LBL-024 is named as a drug or biological intervention in 8 clinical trials in our China trial register, 6 of which are recruiting. The lead sponsor is Nanjing Leads Biolabs Co.,Ltd. Registered phases: Phase 1/2, Phase 2 and Phase 3. Conditions studied include Advanced Solid Tumour; Advanced Melanoma; Triple Negative Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Solid Tumour | 3 |
| Advanced Melanoma | 1 |
| Triple Negative Breast Cancer | 1 |
| Metastatic Colorectal Carcinoma | 1 |
| Ovarian Cancer | 1 |
| Advanced Extrapulmonary Neuroendocrine Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Nanjing Leads Biolabs Co.,Ltd | 8 |
| Register | LBL-024 trials |
|---|---|
| Clinical trials in China | 8 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how LBL-024 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LBL-024 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.